In addition, analysis of CpGs in the promoter region of FFAR3 demonstrated markedly lower methylation in obese patients and patients with T2DM, which increased in obese patients over the intervention period, thus showing a significant correlation between a higher body mass index and lower methylation of FFAR3. This evidence concerns the gene FFAR3 and type 2 diabetes mellitus.